CD274 and neoplasm: Currently, several biomarkers, such as PD-L1 expression, tumor mutational burden, tumor-infiltrating lymphocytes (TILs), and imaging modalities, have been studied in this context, albeit primarily showing prognostic utility, rather than a predictive role for immunotherapy benefit1,22.